Home LiteratureArticle Details
PMID: 18337586 Published · ppublish English Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease.

Neurology ·Vol. 70 ·No. 16 Pt 2 ·2008-04-15 ·Pages 1456-60

Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, De Deyn PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols WC, Hagenah J, Klein C, Samii A, Zabetian CP, Bonifati V, Van Broeckhoven C, Farrer MJ, Wszolek ZK

Abstract

Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common cause of Parkinson disease (PD). Several dominantly inherited pathogenic substitutions have been identified in different domains of the Lrrk2 protein. Herein, we characterize the clinical and genetic features associated with Lrrk2 p.R1441C. We identified 33 affected and 15 unaffected LRRK2 c.4321C>T (p.R1441C) mutation carriers through an international consortium originating from three continents. The age-specific cumulative incidence of PD was calculated by Kaplan-Meier analysis. The clinical presentation of Lrrk2 p.R1441C carriers was similar to sporadic PD and Lrrk2 p.G2019S parkinsonism. The mean age at onset for parkinsonism was 60 years, range 30-79 years; fewer than 20% of the patients had symptoms before the age 50 years, while by 75 years >90% of them had developed symptoms. Haplotype analysis suggests four independent founders for the p.R1441C mutation. The distribution in age at onset and clinical features in Lrrk2 p.R1441C patients are similar to idiopathic and Lrrk2 p.G2019S parkinsonism. Several independent founders of the p.R1441C substitution suggest this site is prone to recurrent mutagenesis.

MeSH Terms
Adult Aged Aged, 80 and over Amino Acid Substitution/genetics Arginine/genetics Cysteine/genetics DNA Mutational Analysis Female Glycine/genetics Haplotypes/genetics Humans Internationality Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Male Middle Aged Parkinson Disease/genetics,physiopathology Parkinsonian Disorders/genetics,physiopathology Protein Serine-Threonine Kinases/genetics Serine/genetics
Chemicals
Serine Arginine LRRK2 protein, human Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Protein Serine-Threonine Kinases Cysteine Glycine
Authors & Affiliations
34 authors, click to expand affiliations / ORCID
Haugarvoll K
Department of Neurology, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA.
Rademakers R
Kachergus J M
Nuytemans K
Ross O A
Gibson J M
Tan E-K
Gaig C
Tolosa E
Goldwurm S
Guidi M
Riboldazzi G
Brown L
Walter U
Benecke R
Berg D
Gasser T
Theuns J
Pals P
Cras P
De Deyn P Paul
Engelborghs S
Pickut B
Uitti R J
Foroud T
Nichols W C
Hagenah J
Klein C
Samii A
Zabetian C P
Bonifati V
Van Broeckhoven C
Farrer M J
Wszolek Z K
References (29)
29 references, click to expand
  1. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
    Mov Disord. 2007 May 15;22(7):982-9 PMID: 17427941
  2. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
    Hum Mol Genet. 2007 Sep 1;16(17):2031-9 PMID: 17584768
  3. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.
    Neuron. 2004 Nov 18;44(4):601-7 PMID: 15541309
  4. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population.
    Neuroreport. 2007 Feb 12;18(3):273-5 PMID: 17314670
  5. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence.
    Hum Genet. 2007 Feb;120(6):857-63 PMID: 17019612
  6. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.
    Biochemistry. 2007 Feb 6;46(5):1380-8 PMID: 17260967
  7. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    J Neurochem. 2007 Oct;103(1):238-47 PMID: 17623048
  8. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia.
    Parkinsonism Relat Disord. 2007 Mar;13(2):89-92 PMID: 17222580
  9. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.
    Mov Disord. 2006 Jul;21(7):997-1001 PMID: 16602113
  10. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.
    N Engl J Med. 2006 Jan 26;354(4):424-5 PMID: 16436782
  11. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor.
    J Med Genet. 2005 Nov;42(11):e65 PMID: 16272257
  12. Parkinson disease: handedness predicts asymmetry.
    Neurology. 2005 Jun 14;64(11):1925-30 PMID: 15955945
  13. Diagnostic criteria for Parkinson disease.
    Arch Neurol. 1999 Jan;56(1):33-9 PMID: 9923759
  14. Parkinsonism: onset, progression and mortality.
    Neurology. 1967 May;17(5):427-42 PMID: 6067254
  15. Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients.
    Eur J Hum Genet. 2008 Apr;16(4):471-9 PMID: 18197194
  16. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease.
    Eur J Hum Genet. 2006 Mar;14(3):322-31 PMID: 16333314
  17. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs.
    N Engl J Med. 2006 Jan 26;354(4):422-3 PMID: 16436781
  18. A new statistical method for haplotype reconstruction from population data.
    Am J Hum Genet. 2001 Apr;68(4):978-89 PMID: 11254454
  19. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.
    Neuron. 2004 Nov 18;44(4):595-600 PMID: 15541308
  20. Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease.
    Mov Disord. 2006 Sep;21(9):1506-10 PMID: 16758483
  21. A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan.
    BMC Neurol. 2006 Dec 22;6:47 PMID: 17187665
  22. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology.
    Neurology. 2004 May 11;62(9):1619-22 PMID: 15136696
  23. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.
    Am J Hum Genet. 2005 Apr;76(4):672-80 PMID: 15726496
  24. Global distribution and reduced penetrance: Lrrk2 R1441C in an Irish Parkinson's disease kindred.
    Mov Disord. 2007 Jan 15;22(2):291-2 PMID: 17089395
  25. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan.
    Neurogenetics. 2006 Jul;7(3):133-8 PMID: 16633828
  26. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
    Arch Neurol. 2006 Mar;63(3):377-82 PMID: 16533964
  27. LRRK2 in Parkinson's disease: protein domains and functional insights.
    Trends Neurosci. 2006 May;29(5):286-93 PMID: 16616379
  28. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.
    Mov Disord. 2006 Dec;21(12):2257-60 PMID: 17078063
  29. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
    Biochem J. 2007 Jul 15;405(2):307-17 PMID: 17447891
Article Info
Journal
Neurology
Abbr.
Neurology
ISSN
1526-632X
Published
2008-04-15
Epub
2008-00-12
Pages
1456-60
Language
English
Region
United States
NLM ID
0401060
PMCID
PMC3906630
Subset
IM
Grants
NINDS NIH HHS · R01 NS37167 · United States
NINDS NIH HHS · K08 NS044138 · United States
Telethon · GTB07001 · Italy
NINDS NIH HHS · R01 NS037167 · United States
NINDS NIH HHS · P50 NS040256 · United States
NINDS NIH HHS · P50 NS40256 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com